Background: Viscosupplementation consists of intraarticular hyaluronic acid injections applied to treat pain and improve joint mobility. The objective of the study was to analyze the improvement of the range of mobility of the first metatarsophalangeal joint with a single dose of cross-linked hyaluronic acid.
Methods: Ten fresh frozen specimens of feet sectioned below the knee were selected.
Background: Haptics-enhanced virtual reality (VR-haptic) simulation in dental education has evolved considerably during the past decade, representing a promising resource of simulation-based training opportunities to support conventional practice. We aim to summarize current literature on the applications of VR-haptics in learning, practicing, and teaching dental education.
Methods: A literature search was performed using PubMed, focusing on research articles published between January 2010 and January 2024.
Materials (Basel)
November 2024
Oral rehabilitation with dental implants has resulted in high success rates. However, some complications have been described, such as the loss of the prosthetic screw. Some manufacturers sell screws with different coatings to avoid screw loosening, but even these types of screws can come loose.
View Article and Find Full Text PDFClin Med Insights Arthritis Musculoskelet Disord
August 2024
We report a first case of hallux rigidus successfully treated in an elderly patient by intra-articular infiltration of cross-linked hyaluronic acid (HA) 21 mg/mL with mannitol (Desirial Plus) and review the previous literature on the different compositions of HA infiltrative treatment applied to hallux rigidus. A 77-year-old female patient with moderate unilateral pain of 6 months of evolution and stiffness of the movement of the first metatarsophalangeal joint of the left foot, corresponding to grade 2 of the classification proposed by Coughlin and Shurnas. The objective of the study was to perform a pilot test to (a) evaluate the correct technique of intra-articular infiltration as well as (b) the use of a commercial cross-linked HA 21 mg/mL with mannitol, to a voluntary patient diagnosed with hallux rigidus.
View Article and Find Full Text PDF